Inhibiting NLRC5 for hemolytic and inflammatory diseases
Inhibiting the cytosolic pathogen recognition receptor NLRC5 could help treat hemolytic and inflammatory diseases by preventing formation of the cell death PANoptosome complex in blood cells via interaction with NLRP12.
In bioinformatic analysis of public data sets, NLRC5 expression was higher in red blood cells from the blood and bone marrow of malaria patients than of individuals without malaria. In bioinformatic analysis of separate public data sets, NLRC5 expression was higher in blood monocytes and bone marrow hematopoietic stem cells from sickle cell disease patients than from individuals without sickle cell disease. ...
BCIQ Company Profiles
BCIQ Target Profiles